The Division of Surgical Sciences Bruce Sullenger’s, PhD, Professor of Surgery, lab partnered with Shahid Nimjee, MD, PhD, Co-Founder and Chief Medical Officer, Basking Biosciences to translate a new therapeutic approach into the clinic.
The clinical study titled “Randomized, Double-blind, Placebo-controlled Phase 1 Study of vWF-binding Aptamer, BB-031: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity in Healthy Volunteers” was presented at the American Heart Association Meeting in Dallas, TX on Thursday, February 9.
Click here to read the press release announcing the presentation phase of this clinical study.